Ellie MD has more of the right pieces than its rating suggests. Hormone therapy is available, titration happens quarterly on the basis of how you respond, and 503A compounding sits behind the dosing. Any one of those puts it ahead of a plain async service.
What holds it in the middle of the Charter is that weight care runs on its own track, separate from everything else. For a reader whose central complaint is being treated as a collection of unrelated symptoms, a provider organised into separate tracks is an uncomfortable fit even when each track is competent.
Here is how Ellie MD reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Doses are reviewed and adjusted on a quarterly cycle rather than a fixed ladder, backed by 503A compounding — which is why dose fit is the strongest row here. At $239 that is fairly priced for response-based care. Being believed and metabolic framing both score partial: the practice has the clinical range, but nothing published joins it into one view of a patient.
Because the tracks are separate, carrying information between them falls to you. That is manageable if you are organised and well-informed about your own condition, and wearing if you have already spent years being your own case manager. Ellie MD also publishes no maintenance or step-down plan and no accountability structure, which is what pulls the rating down more than anything to do with the dosing itself.
Put these to Ellie MD in writing, and keep the reply.
Ellie MD does the dosing genuinely well and leaves the joining-up to you. If you have the energy to coordinate and want real titration at a fair price, the clinical substance is here. If what you need is to stop coordinating, this is not that.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.